Clinical Trial Update: Immunotherapy of CD8+NKG2D+ AKT Cell With Chemotherapy to Pancreatic Cancer [EARLY_Phase 1]

View source ↗

Summary

Early-phase trial update investigating autologous CD8+NKG2D+ AKT T-cell therapy combined with chemotherapy for pancreatic ductal adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Autologous CD8+NKG2D+ AKT T-cell therapy (CD8+NKG2D+ AKT T-cell therapy)

Snippet

Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Conditions: Pancreatic Ductal Adenocarcinoma | EARLY_Phase 1 | Status: UNKNOWN